- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02004782
Barretts oEsophageal Resection With Steroid Therapy Trial (BERST)
Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.
Barretts mucosa is a premalignant condition of the oesophagus, which can progress to cancer. Oesophageal cancer is aggressive, with a 5 year survival of only ~15%. High risk Barretts mucosa, containing high grade dysplasia or early cancer, can be removed by endoscopic mucosal resection (EMR) during gastroscopy. If patients can be effectively treated by EMR while they have premalignant or early malignant disease, it is a curative procedure.
Currently, the major limitation of Complete Barretts Excision (CBE) by EMR, is scar tissue development in the oesophagus, leading to stricture formation and difficulty swallowing (dysphagia). If a safe and effective method could be found to reduce this risk, the treatment options for early oesophageal cancer would be greatly improved. CBE is performed as a two stage procedure, with 2 gastroscopies 8 weeks apart. In this randomised, doubleblind study, eligible and enrolled patients are randomised after the 1st stage CBE to receive either prednisolone tablets or placebo. Inclusion criteria are patients with short segment (<3cm circumferential disease) Barretts oesophagus with high grade dysplasia or early cancer. The treatment period is for 6 weeks after both CBE sessions. Prednisolone is given in a reducing dose over the 6 weeks, starting at 40mg daily.
The primary outcome is symptomatic dysphagia development. Endoscopic dilation will be performed as required for dysphagia secondary to symptomatic oesophageal stricture formation persisting for ≥2 days, or complete dysphagia for any time period. Endoscopic surveillance with biopsies will occur at a 3 month, 6 month then 12 month interval following CBE, to assess for complete removal of Barretts mucosa.
Following two stage CBE, stricture rates without preemptive therapy in noncircumferential, circumferential <2cm, and circumferential <3cm disease, are estimated to be 30%, 50% and 70% respectively. The investigators predict a 50% reduction in stricture rate with oral steroid therapy. With a primary analyses of oral steroid versus placebo tested at a 5% level of significance in a two tailed test, 58 patients are needed per group. Allowing for a 5% drop out rate, a total of 126 patients are required. The study will be performed at five Australian Tertiary Hospitals, and the recruitment period is estimated to be 2 years.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Rebecca Sonson
- Phone Number: 0298459779
- Email: bec2153@gmail.com
Study Contact Backup
- Name: Michael Bourke
- Phone Number: 98459779
- Email: michael@citywestgastro.com.au
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
Contact:
- Rebecca Sonson
- Phone Number: 98459779
- Email: Rebecca.Sonson@health.nsw.gov.au
-
Principal Investigator:
- Michael Bourke, MBBS FRACP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed Barretts mucosa with High Grade Dysplasia or early adenocarcinoma (T1a, intramucosal adenocarcinoma).
- Barretts segment ≥ 30% circumference, ≤C3 and ≤M5.
- The general health condition of the patient permits anaesthesia for endoscopy.
- Patient is 18 years of age or older.
- Informed consent is obtained
Exclusion Criteria:
- Previous (referral) biopsies show low grade dysplasia only, or invasive adenocarcinoma.
- Barretts segment <30% circumference, >C3 or >M5.
4. During initial gastroscopy there are highly suspicious areas for submucosal invasive cancer (Kudo pit pattern type V; excavated/depressed type morphology; large smooth or ulcerated nodule). In cases of significant doubt, initial resection is of the highly suspicious area only, and urgent histology processing requested. If submucosal invasion is excluded, the patient is rebooked for 1st stage CBE (60% circumferential resection) and randomization after a 4-6 weeks interval.
4. Presence of a tight peptic oesophageal stricture that impedes safe and effective EMR using the Duette cap.
5. Active malignancy, uncontrolled Diabetes Mellitus, active or untreated major psychiatric disorder, uncontrolled infection, uncontrolled hypertension, uncontrolled or severe congestive cardiac failure, non-correctable coagulopathy (INR>2, or platelet count <60 x 109/L), osteoporosis, recent peptic ulcer disease, moderate-to-severe glaucoma or untreated glaucoma, or pregnancy.
6. Unable to provide informed consent 7. Allergy to compound used in tablet formulation: Microcrystalline cellulose (MCC).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prenisolone
Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6.
Prednisolone is taken in the morning.
Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge.
The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
|
Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6.
Prednisolone is taken in the morning.
Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge.
The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
|
Placebo Comparator: Placebo
Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6.
Placebo is taken in the morning.
Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge.
The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
|
Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6.
Placebo is taken in the morning.
Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge.
The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of symptomatic stricture formation
Time Frame: >2 days
|
Rate of symptomatic oesophageal stricture formation.A symptomatic stricture is defined as a stricture leading to the inability to tolerate a soft diet for ≥ 2 days, or the presence of complete dysphagia for any length of time.
|
>2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dilations
Time Frame: Two weeks or more
|
The need for, and number of endoscopic dilations.
|
Two weeks or more
|
Dysphagia score
Time Frame: 3, 6 and 12 months
|
Dysphagia score (DS) at 3, 6 and 12 month surveillance endoscopies.
DS: 0 = Normal diet; 1 = Some solid foods; 2 = Semi-solid foods; 3 = Liquids only; 4 = Total dysphagia
|
3, 6 and 12 months
|
Stricture formation
Time Frame: 3, 6, 12 months
|
Endoscopic evidence of stricture formation at 3, 6 and 12 month surveillance endoscopies.
No stricture, mild stricture, moderate stricture ('hugs' the gastroscope but the gastroscope can pass), severe stricture (cannot be passed with the gastroscope)
|
3, 6, 12 months
|
Recurrence
Time Frame: 3, 6 and 12 months
|
Recurrence of Barretts mucosa, defined as the presence of Barretts mucosa endoscopically, or mucosal columnar epithelium with or without intestinal metaplasia on surveillance biopsies.
Measured at 3-month surveillance (20 weeks post 1st CBE), 6 month surveillance (46 weeks post 1st CBE), and 12 month surveillance (98 weeks post 1st CBE) endoscopies.
|
3, 6 and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost
Time Frame: 0-12 months
|
The direct medical costs and indirect non-medical costs of production lost will be calculated based on Australian Medical guidelines, and compared between each treatment strategy.
|
0-12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Bourke, Western Sydney Local Health District
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Gastrointestinal Diseases
- Esophageal Diseases
- Precancerous Conditions
- Barrett Esophagus
- Esophageal Stenosis
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisolone
Other Study ID Numbers
- HREC2013/7/4.5(3702)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Barrett Esophagus
-
Erbe Elektromedizin GmbHNAMSA; Kansas City Veteran Affairs Medical Center; Erbe USA IncorporatedTerminatedBarrett's Esophagus | High-grade Dysplasia in Barrett Esophagus | Low Grade Dysplasia in Barrett EsophagusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedBarrett Esophagus | Barrett AdenocarcinomaNetherlands
-
University Medical Center GroningenCompletedEsophageal Cancer | Barrett Esophagus | Dysplasia in Barrett EsophagusNetherlands
-
Mayo ClinicTerminatedBarretts Esophagus With High Grade Dysplasia | Barrett AdenocarcinomaUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaboratorsNot yet recruitingEsophageal Cancer | Barrett Adenocarcinoma | Barretts Esophagus With Dysplasia
-
Portsmouth Hospitals NHS TrustUniversity of PortsmouthUnknownBarrett Esophagus | Barrett Adenocarcinoma | Barrett Metaplasia | Barrett Oesophagitis With DysplasiaUnited Kingdom
-
Professor Michael BourkeWithdrawn
-
Lucid Diagnostics, Inc.RecruitingBarrett Esophagus | Barretts Esophagus With Dysplasia | Esophagus AdenocarcinomaUnited States
-
Medical University of South CarolinaCompletedBarretts Esophagus With DysplasiaUnited States
-
Allegheny Singer Research Institute (also known...Integra LifeSciences CorporationTerminatedBarrett Esophagus | High Grade Dysplasia | EsophagusUnited States
Clinical Trials on Prednisolone
-
Children's Hospital of PhiladelphiaCompleted
-
Assiut UniversityCompleted
-
Hamamatsu UniversityCompletedChronic Disease | Eosinophilic PneumoniaJapan
-
Sparrow PharmaceuticalsRecruitingPolymyalgia RheumaticaGermany
-
IsalaCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
Institute of Child HealthUnknown
-
Postgraduate Institute of Medical Education and...Completed
-
Postgraduate Institute of Medical Education and...CompletedPost COVID-19 Diffuse Lung DiseaseIndia
-
Nanjing University School of MedicineCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity Medical Center Groningen; Imperial College London; University Hospitals... and other collaboratorsTerminatedWegener's Granulomatosis | Microscopic PolyangiitisUnited Kingdom